UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1424-2
Program Prior Authorization/Notification
Medication Zurzuvae® (zuranolone)
P&T Approval Date 12/2023, 12/2024
Effective Date 3/1/2025
1. Background:
Zurzuvae is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive
modulator indicated for the treatment of postpartum depression (PPD) in adults.
2. Coverage Criteriaa:
A. Authorization
1. Zurzuvae will be approved based on both of the following criteria:
a. Diagnosis of postpartum depression (PPD)
-AND-
b. Onset of current depressive episode was during the third trimester or within 4 weeks
postpartum
Authorization will be issued for 1 month.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class
• Supply limits may be in place.
4. References:
1. Zurzuvae [package insert]. Cambridge, MA; Biogen Inc.; July 2024.
© 2024 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification – Zurzuvae (zuranolone)
Change Control
12/2023 New program.
12/2024 Annual review without changes to clinical criteria. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
2